Human PERK Antibody

Detection of Human PERK by Western Blot. Western blot shows lysates of HepG2 human hepatocellular carcinoma cell line and NTera-2 human testicular embryonic carcinoma cell line. PVDF membrane was probed with 1 µg/mL of Human PERK Antigen Affinity-purified Polyclonal Antibody (Catalog # AF3999) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF017). A specific band was detected for PERK at approximately 130 kDa (as indicated). This experiment was conducted using Immunoblot Buffer Group 1.

Western Blot Shows Human PERK Specificity by Using Knockout Cell Line. Western blot shows lysates of HeLa human cervical epithelial carcinoma parental cell line and PERK knockout HeLa cell line (KO). PVDF membrane was probed with 1 µg/mL of Goat Anti-Human PERK Antigen Affinity-purified Polyclonal Antibody (Catalog # AF3999) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF017). A specific band was detected for PERK at approximately 150 kDa (as indicated) in the parental HeLa cell line, but is not detectable in knockout HeLa cell line. GAPDH (Catalog # AF5718) is shown as a loading control. This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

Detection of Human PERK by Western Blot Activation of the ER stress signaling pathway leads to the LX-2 cell apoptosis induced by VP-16.(a) Western blotting analysis of ER stress-associated proteins in LX-2 cells after treatment with VP-16 for 72 h. (b) After exposure to VP-16 for 72 h, the protein phosphorylation levels of PERK and eIF2 alpha were analyzed by western blotting. (c) After exposure to VP-16 for 72 h, the proteins of the IRE1 alpha /ASK1/JNK signaling pathway were analyzed by western blotting. (d,e) LX-2 cells were pretreated with a JNK inhibitor (SP600125, 40 μM) for 1 h, and then treated with 4 μM VP-16 for 72 h. (d) Cell viability was measured using the CCK-8 assay. The percentage of apoptosis cells was analyzed by flow cytometry. The data are presented as the mean ± SD of at least three independent experiments performed in triplicates. **P < 0.01, compared with the group treated with VP-16 alone. (e) Western blotting analysis of the cell lysates was performed using the indicated antibodies. In all of the western blotting analyses, beta -actin was used as a loading control. *P < 0.05, compared with the control group. #P < 0.05, compared with the group treated with VP-16 alone. Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/27680712), licensed under a CC-BY license. Not internally tested by R&D Systems.